Pages that link to "Q43674732"

The following pages link to Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). (Q43674732):

Displaying 203 items.

• Reverse transcription of the HIV-1 pandemic (Q22242815) (← links)
• Adherence and drug resistance: predictions for therapy outcome (Q27477742) (← links)
• Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations (Q28235418) (← links)
• In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues (Q28343615) (← links)
• Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice (Q28343930) (← links)
• Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine (Q28344137) (← links)
• A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine (Q28379499) (← links)
• Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years (Q28379519) (← links)
• "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice (Q28477270) (← links)
• Patterns of transmitted HIV drug resistance in Europe vary by risk group (Q28537726) (← links)
• Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro (Q28542490) (← links)
• Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. (Q29619254) (← links)
• Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee (Q33442370) (← links)
• Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients (Q33586790) (← links)
• Managing resistance to anti-HIV drugs: an important consideration for effective disease management. (Q33588535) (← links)
• Selection of drug-resistant HIV. (Q33594382) (← links)
• Evolutionary dynamics of HIV-induced subversion of the immune response (Q33683341) (← links)
• Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients (Q33699597) (← links)
• British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). (Q33711667) (← links)
• A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. (Q33728690) (← links)
• Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase (Q33737755) (← links)
• Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication (Q33743954) (← links)
• A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine (Q33782477) (← links)
• Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy (Q33782492) (← links)
• Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro (Q33782815) (← links)
• Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy (Q33784635) (← links)
• Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy (Q33825371) (← links)
• Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals (Q33839756) (← links)
• Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay (Q33843999) (← links)
• Genotypic testing for human immunodeficiency virus type 1 drug resistance (Q33906239) (← links)
• Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase (Q33961507) (← links)
• Incidence and impact of resistance against approved antiretroviral drugs (Q33966248) (← links)
• A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC) (Q33976011) (← links)
• Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine (Q33977402) (← links)
• Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus (Q33981009) (← links)
• Inhibitors of HIV-1 reverse transcriptase (Q34050684) (← links)
• Antiretroviral therapy for human immunodeficiency virus infection in 1997 (Q34185841) (← links)
• Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase (Q34339657) (← links)
• Differential susceptibility of retroviruses to nucleoside analogues (Q34349394) (← links)
• Virus population dynamics, fitness variations and the control of viral disease: an update (Q34452529) (← links)
• Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. (Q34465037) (← links)
• Rapid emergence of protease inhibitor resistance in hepatitis C virus (Q34551913) (← links)
• The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies (Q34625250) (← links)
• The HBV drug entecavir - effects on HIV-1 replication and resistance (Q34639926) (← links)
• Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. (Q34644794) (← links)
• The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase (Q34668716) (← links)
• Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. (Q34677368) (← links)
• HIV-1 genotypic and phenotypic resistance (Q34876000) (← links)
• Antivirals against HIV-1. (Q34876093) (← links)
• 4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication (Q34933164) (← links)
• HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya (Q34968326) (← links)
• HIV-1 drug resistance: can we overcome? (Q34974754) (← links)
• Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening (Q35014297) (← links)
• Managing failure to antiretroviral drugs in HIV-1-infected patients (Q35063764) (← links)
• Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors (Q35130447) (← links)
• Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice (Q35139305) (← links)
• Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine (Q35139503) (← links)
• High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. (Q35156558) (← links)
• Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. (Q35363594) (← links)
• Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase (Q35548123) (← links)
• Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase (Q35566910) (← links)
• Update on HIV resistance and resistance testing (Q35574598) (← links)
• Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1 (Q35579833) (← links)
• Hepatitis B viral resistance: mechanisms and diagnosis (Q35621686) (← links)
• Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus (Q35621741) (← links)
• Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? (Q35636514) (← links)
• A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies (Q35742512) (← links)
• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection (Q35752812) (← links)
• Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. (Q35870930) (← links)
• Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. (Q35874788) (← links)
• Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. (Q35878689) (← links)
• A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides (Q35879410) (← links)
• Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. (Q35905947) (← links)
• Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. (Q35964704) (← links)
• Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures (Q36086642) (← links)
• Virus dynamics and drug therapy (Q36244920) (← links)
• Converting cancer therapies into cures: lessons from infectious diseases (Q36301709) (← links)
• Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants (Q36313247) (← links)
• Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection (Q36322100) (← links)
• Biochemical mechanism of HIV-1 resistance to rilpivirine (Q36368294) (← links)
• Antiretroviral therapy 2006: pharmacology, applications, and special situations (Q36533088) (← links)
• Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group (Q36536351) (← links)
• Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma (Q36542026) (← links)
• Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles (Q36548250) (← links)
• Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors (Q36689086) (← links)
• Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate (Q36703003) (← links)
• Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants (Q36747913) (← links)
• Antiretroviral treatment of HIV infection: Swedish recommendations 2007. (Q36852859) (← links)
• Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques (Q36954674) (← links)
• Clinical significance of human immunodeficiency virus type 1 replication fitness (Q36969857) (← links)
• The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. (Q37018369) (← links)
• HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. (Q37090735) (← links)
• Reverse transcriptase inhibitors as potential colorectal microbicides (Q37190754) (← links)
• How effectively can HIV phylogenies be used to measure heritability? (Q37363152) (← links)
• Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile (Q37409900) (← links)
• Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay (Q37497318) (← links)
• Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine (Q37590309) (← links)
• Viral dynamics in hepatitis B virus infection (Q37638400) (← links)
• Lamivudine for the treatment of HIV. (Q37650410) (← links)
• HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. (Q37935116) (← links)
• Drug resistance in HIV-1. (Q37967710) (← links)
• Targets for inhibition of HIV replication: entry, enzyme action, release and maturation (Q37979697) (← links)
• The high cost of fidelity (Q38158093) (← links)
• Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea (Q38524490) (← links)
• Emerging drugs for the treatment of hepatitis B. (Q38759805) (← links)
• A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. (Q38759997) (← links)
• No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations (Q39191315) (← links)
• Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus (Q39451785) (← links)
• Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance (Q39459306) (← links)
• Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler (Q39464149) (← links)
• A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V (Q39473036) (← links)
• Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice (Q39476701) (← links)
• Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy (Q39557921) (← links)
• Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. (Q39564517) (← links)
• Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance (Q39577975) (← links)
• Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice (Q39590154) (← links)
• The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis (Q39590457) (← links)
• Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection (Q39591902) (← links)
• Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014. (Q39638378) (← links)
• Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies (Q39684476) (← links)
• Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase (Q39720877) (← links)
• Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay (Q39782999) (← links)
• Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase (Q39785298) (← links)
• Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity (Q39796529) (← links)
• Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase (Q39879230) (← links)
• Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture (Q40291316) (← links)
• Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants (Q40674710) (← links)
• Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles (Q40783234) (← links)
• Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients (Q40800372) (← links)
• Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice (Q40884087) (← links)
• Antiretroviral agents. Current usage (Q40900124) (← links)
• Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine (Q40937905) (← links)
• Primary care of the HIV patient: standard practice and new developments in the era of managed care (Q40977715) (← links)
• Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients (Q41141601) (← links)
• Treatment of HIV infection. Tolerability of commonly used antiretroviral agents (Q41175137) (← links)
• HIV-1: gambling on the evolution of drug resistance? (Q41368666) (← links)
• Antiretroviral therapy for pregnant women (Q41378473) (← links)
• The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy (Q41413114) (← links)
• Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection (Q41429010) (← links)
• Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. (Q41516241) (← links)
• Antiretroviral therapy in adults (Q41583561) (← links)
• Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model. (Q41603336) (← links)
• Antiretroviral therapy in the pregnant woman (Q41682612) (← links)
• Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections (Q41719005) (← links)
• A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation. (Q41862836) (← links)
• HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. (Q41879018) (← links)
• Dynamics of hepatitis B virus resistance to lamivudine (Q41908360) (← links)
• Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. (Q41950632) (← links)
• Targeted resequencing of HIV variants by microarray thermodynamics. (Q42277508) (← links)
• Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages (Q42536472) (← links)
• Antiretroviral monotherapies and serum HIV-1 dynamics (Q42948288) (← links)
• Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics (Q42999813) (← links)
• Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals (Q43173413) (← links)
• Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival (Q43413064) (← links)
• Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation (Q43635554) (← links)
• The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response (Q43993272) (← links)
• Antiretroviral drug resistance among HIV-1 infected children failing treatment. (Q44134172) (← links)
• Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation (Q44170295) (← links)
• Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs (Q44355582) (← links)
• Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. (Q44355905) (← links)
• Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance (Q44481687) (← links)
• Emerging transmitted drug resistance in treatment-naïve human immunodeficiency virus-1 CRF06_cpx-infected patients in Estonia (Q44681515) (← links)
• Complete hepatitis B virus genome analysis in chronically infected children before and during lamivudine treatment (Q44795512) (← links)
• Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro (Q44820781) (← links)
• Factors associated with resistance to human immunodeficiency virus protease inhibitors (Q45158683) (← links)
• A siege of hepatitis: fighting a defiant virus (Q45368430) (← links)
• Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort (Q45714051) (← links)
• Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients (Q45746181) (← links)
• Advances in the treatment of chronic hepatitis B virus infection. (Q45748510) (← links)
• RNA virus fitness. (Q45748520) (← links)
• Anti-human immunodeficiency virus drug combination strategies (Q45752028) (← links)
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group (Q45755649) (← links)
• Protein promiscuity: drug resistance and native functions--HIV-1 case (Q46074569) (← links)
• Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages (Q46450181) (← links)
• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection (Q46571276) (← links)
• The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V. (Q46718140) (← links)
• Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine (Q46914719) (← links)
• High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia (Q47547186) (← links)
• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study (Q48565770) (← links)
• Pre-existence and emergence of drug resistance in HIV-1 infection. (Q52264204) (← links)
• Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. (Q52374199) (← links)
• Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. (Q53940587) (← links)
• [Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. (Q53966961) (← links)
• Development of novel nucleoside analogues for use against drug resistant strains of HIV-1. (Q54034689) (← links)
• Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. (Q54077659) (← links)
• Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. (Q54386002) (← links)
• Aciclovir for dual infection with HIV and HSV (Q56961830) (← links)
• HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials (Q57207278) (← links)
• Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development? (Q58815987) (← links)
• Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques (Q64128826) (← links)
• Antiretroviral therapy (Q71828771) (← links)
• Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy (Q73010766) (← links)
• Antiretroviral Drug Resistance in HIV-1 (Q73235205) (← links)
• Hidden dangers of incompletely suppressive antiretroviral therapy (Q73368831) (← links)
• Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox? (Q74782661) (← links)
• Transmission of antiretroviral-drug-resistant HIV-1 variants (Q78213010) (← links)
• Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates (Q79252224) (← links)
• HIV resistance to antiviral drugs: public health implications (Q80098606) (← links)
• Synthesis and evaluation of 2'-substituted cyclobutyl nucleosides and nucleotides as potential anti-HIV agents (Q80159514) (← links)
• Inhibitors of HIV-1 reverse transcriptase (Q80215893) (← links)
• Individualisation of HIV therapy based on HIV RNA load: the virologist's perspective (Q81605739) (← links)
• Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication (Q92691723) (← links)
• Linked dual-class HIV resistance mutations are associated with treatment failure (Q93122212) (← links)